Negative Phase 2 Trial Data Ends Development of PSP Drug Negative Phase 2 Trial Data Ends Development of PSP Drug

Phase 2 trial results show gosuranemab did not meet primary or key secondary endpoints in patients with progressive supranuclear palsy, leading to discontinuation of the drug ' s development for PSP.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news